GFAP and neuromyelitis optica: Fig. 6 (left) shows that C1-inh did not protect against NMO pathology produced by NMO-IgG injection at day 2, as seen by large areas with loss of AQP4 and GFAP (white lines) or AQP4 alone (‘penumbra region’, dashed white lines). Fig. 6 (right) summarizes areas of loss of AQP4 and GFAP immunofluorescence.